LLY
ELI LILLY & Co
NYSE · Healthcare · Drug Manufacturers - General · US
$1,136.98
−0.11%Price chart
Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15
Key dataSep 15, 2026
Open$1,156.63
From 52W high−11.20%
Volume1.80M
Market cap$1.07T
P/E (TTM)38.1x
P/S (TTM)13.4x
Div yield0.59%
Key dataSep 15, 2026
Open
$1,156.63
From 52W high
−11.20%
Volume
1.80M
Market cap
$1.07T
ValuationView details →
P/E (Fwd)
27.8x
EV/EBITDA
31.7x
P/E (TTM)
38.1x
RSI (14)
44.2
MomentumView details →
1D Return
−0.11%
YTD Return
+6.46%
SummaryUpdated Jun 1, 2026
Eli Lilly and Company (NYSE:LLY) is a major American pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company has evolved from a small Indianapolis pharmacy into one of the world's largest pharmaceutical manufacturers, with a particular focus on diabetes care, oncology, immunology, and neuroscience. Lilly went public in 1972 and has established itself as a leader in innovative drug development, with recent breakthrough success in diabetes and obesity treatments that have transformed both the company's financial performance and market position in the healthcare sector.
Similar companies
Latest newsMore news →
Eli Lilly said its oral weight-loss drug Foundayo has captured more than 30% of new US patients on oral obesity treatments, narrowing Novo Nordisk's early lead with its Wegovy pill.1d agoAmplia Therapeutics entered into a Clinical Trial Collaboration and Supply Agreement with Eli Lilly to evaluate narmafotinib combined with olomorasib in non-small cell lung cancer.42d agoEli Lilly expects to launch its oral weight-loss drug across Europe and Britain in the second half of 2026 or early 2027.79d ago